N/A
N=10
Cross-over Comparison of Gabapentin and Memantine as Treatment for Acquired Nystagmus
Nystagmus
Bottom Line
View on ClinicalTrials.gov: NCT00928954 ↗Enrolled (actual)
10
Serious AEs
0.0%
Results posted
Jul 2016
Primary outcome: Primary: Change in logMAR Visual Acuity of Each Eye, Measured During Far or Near Viewing — 0; 0.1; 0.2; 0.2 logMAR
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- gabapentin (Drug); memantine (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Case Western Reserve University
- Primary completion
- May 2009
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in logMAR Visual Acuity of Each Eye, Measured During Far or Near Viewing |
0; 0.1; 0.2; 0.2; 0.1; 0.2 | — |
| PRIMARY Percent Change in Median Eye Speed |
-59.1; -21.5; -69.8; -35.1; -19.9; -26.0 | — |
Summary
Involuntary oscillations of the eyes (nystagmus) impairs vision so that affected patients, who have neurological disorders such as Multiple Sclerosis (MS) , cannot read or watch TV. Two medicines have been reported to suppress nystagmus and improve vision in such patients: gabapentin and memantine. The investigators set out to test which of these two drug was more effective by carrying out a double-blind cross-over study. In this way, we could determine which drug worked best in each patient.
Eligibility Criteria
Inclusion Criteria
- Adult (18 years or older) males or females with acquired nystagmus that is degrading their vision
Exclusion Criteria
- Pregnant women
- Individuals who cannot describe their visual symptoms, cooperate with testing, or give informed consent
- Individuals with intolerance of gabapentin or memantine
Data sourced from ClinicalTrials.gov (NCT00928954). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.